secwatch.observer — SEC 8-K summary
======================================

Issuer:     BAXTER INTERNATIONAL INC (BAX)
CIK:        0000010456
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001628280-24-019783
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Baxter Q1 2024: sales $3.59B (+3% CC), adj. EPS $0.65, beating guidance; FY2024 adj. EPS guidance $2.88-$2.98
--------------------------------------------------------------------------------

- Q1 sales $3.59B (+2% reported, +3% CC); GAAP EPS $0.07; adj. EPS $0.65, above guidance.
- FY 2024 guidance: sales growth ~2% reported, 2-3% CC; adj. EPS $2.88-$2.98.
- FDA clearance for Novum IQ large volume infusion pump and Dose IQ Safety Software.
- CEO cited solid operational execution and benefits from new operating model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/10456/000162828024019783/0001628280-24-019783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/10456/000162828024019783/bax-20240502.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-019783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer